Navigation Links
QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

QuatRx CEO will present an update on QuatRx clinical development programs including review of positive results from the Phase 3 pivotal trial for

Ophena(TM) (ospemifene)

ANN ARBOR, Mich., Jan. 4 /PRNewswire/ -- QuatRx Pharmaceuticals Company today announced that the company chief executive officer, Robert L. Zerbe, M.D., will be a presenter at the 26th Annual JP Morgan Healthcare Conference on Tuesday, January 8th, 2008, at 9:30 a.m., Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco from January 7 to 10, 2008.

Dr. Zerbe will present an update on clinical development programs at QuatRx including a review of the positive results from a pivotal phase 3 trial for Ophena(TM) (ospemifene) for the treatment of postmenopausal vaginal syndrome (PVS). Results of the pivotal phase 3 trial for Ophena(TM) were announced by QuatRx on January 3, 2008.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active clinical development and two preclinical development programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Asord(TM) (becocalcidiol), a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, CollaGenex Pharmaceuticals, Inc. QuatRx's two preclinical small molecule programs are designed to address common endocrine disorders in women and men. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... 2014 Reports from CDC ... suffer from one or more chronic health conditions - ... can address some of these diseases, but may not ... sufferers face. While implanted nerve stimulation devices today offer ... nerve, which can induce side effects. , To ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced ... Global Healthcare Unplugged Conference in Key,Biscayne, FL to Thursday, ... p.m. PT.,Previously, the presentation had been scheduled for 9:20 ... and Chief Executive Officer of,Amylin Pharmaceuticals, will be providing ...
... DIEGO, April 30 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... Bank 33rd Annual Health Care Conference on May 6 ... to be webcast live,and may be accessed through a ... http://www.gen-probe.com . The webcast will be available for 30,days ...
... Marks a New Step in the Company,s Global ... Sigma-Aldrich (Nasdaq:,SIAL) today announced the full integration of ... brands effective May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., ... our products and,services," said Josef Zihlmann, Global Vice ...
Cached Biology Technology:Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... genetic susceptibility to epilepsy and migraine. Findings published in ... Against Epilepsy (ILAE), indicate that having a strong family ... migraine with aura (MA). Medical evidence has ... this co-occurrence is called "comorbidity." Previous studies have found ...
... individuals with agonizing pain, it is a cruel blow when ... whose pain gets worse when treated with morphine may be ... January 6 on-line edition of Nature Neuroscience . ... can increase pain, and suggests potential new ways to make ...
... . Many of the nation,s foremost authorities on ... the inaugural Cyber Sciences Laboratory workshop. The event will feature ... The Next Threat to National Security and What to do ... 44 research talks and 20 research posters. Researchers from nine ...
Cached Biology News:All in the family: A genetic link between epilepsy and migraine 2The pain puzzle: Uncovering how morphine increases pain in some people 2The pain puzzle: Uncovering how morphine increases pain in some people 3January 2013 story tips from Oak Ridge National Laboratory 2
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Biology Products: